Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orthovita's Rhakoss enters spinal implant trials:

This article was originally published in Clinica

Executive Summary

Orthovita is pressing ahead with plans to support an application for European approval of its Rhakoss synthetic bone spinal implant by starting clinical trials of the device. The trials are to include the study of the product in 75 patients undergoing cervical spinal fusion surgery. Rhakoss is made of Orthobone, a proprietary biomaterial developed by Malvern, Pennsylvania-based Orthovita. It is designed to provide a synthetic alternative to structural cadaver bone with unique bioactive and bone bonding characteristics, says the company.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT065997

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel